Òscar Reig
About
Òscar Reig is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Òscar Reig has authored 56 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Òscar Reig's work include Prostate Cancer Treatment and Research (20 papers), Renal cell carcinoma treatment (15 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Òscar Reig is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Renal cell carcinoma treatment (15 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Òscar Reig collaborates with scholars based in Spain, United States and France. Òscar Reig's co-authors include Begoña Mellado, Natàlia Jiménez, Mercedes Marín‐Aguilera, Pedro L. Fernández, Aleix Prat, Albert Font, Juan José Lozano, Lourdes Mengual, Antonio Alcaraz and María J. Ribal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.
In The Last Decade
Òscar Reig
47 papers receiving 558 citations
Peers
Òscar Reig
Chia‐Chi Lin Taiwan
Prateek Mendiratta United States
Jamie McIntosh United Kingdom
Flavio Mavignier Cárcano Brazil
Tahsin M. Khan United States
Francesca Vignani Italy
Émeline Colomba France
Hielke J. Meulenbeld Netherlands
Irene De Santo Italy
Prabhakar Pandey United States
Citations per year, relative to Òscar Reig Òscar Reig (= 1×)
peers
Chia‐Chi Lin
Countries citing papers authored by Òscar Reig
Since
Specialization
Citations
This map shows the geographic impact of Òscar Reig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Òscar Reig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Òscar Reig more than expected).
Fields of papers citing papers by Òscar Reig
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Òscar Reig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Òscar Reig. The network helps show where Òscar Reig may publish in the future.
Co-authorship network of co-authors of Òscar Reig
This figure shows the co-authorship network connecting the top 25 collaborators of Òscar Reig. A scholar is included among the top collaborators of Òscar Reig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Òscar Reig. Òscar Reig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Alonso‐Gordoa, Teresa, Geòrgia Anguera, Òscar Reig, et al.. (2025). Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. 136. 102925–102925.
2.
Powles, Tom, Ariel Galapo Kann, M. Gross Goupil, et al.. (2025). LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Annals of Oncology. 36. S1634–S1634.
3.
Reig, Òscar, Laurence Crouzet, Andrea Necchi, et al.. (2024). 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1. Annals of Oncology. 35. S515–S516.
4.
McKean, Meredith, Òscar Reig, Elisa Fontana, et al.. (2024). 654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors. Annals of Oncology. 35. S517–S517.
5.
Herreros, Marta García de, Natàlia Jiménez, Leonardo Rodríguez‐Carunchio, et al.. (2024). Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. European Urology Open Science. 70. 86–90.
6.
Rodríguez, A., Caterina Aversa, Leonardo Rodríguez‐Carunchio, et al.. (2023). 2398P Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?. Annals of Oncology. 34. S1220–S1221.
7.
Jiménez, Natàlia, Òscar Reig, Mercedes Marín‐Aguilera, et al.. (2022). Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. Cancers. 14(19). 4757–4757.
8.
Grande, Enrique, Teresa Alonso‐Gordoa, Òscar Reig, et al.. (2022). Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 7(2). 100463–100463.
9.
Rodríguez‐Vida, Alejo, Pablo Maroto, Albert Font, et al.. (2022). Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. British Journal of Cancer. 128(1). 21–29.
10.
Marín‐Aguilera, Mercedes, Natàlia Jiménez, Òscar Reig, et al.. (2021). Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. Cancers. 13(19). 4960–4960.
11.
Velasco, Guillermo de, Òscar Reig, Francesco Massari, et al.. (2021). Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. British Journal of Urology. 128(2). 254–261.
12.
Reig, Òscar, Akhilesh Mishra, Alana Christie, et al.. (2021). Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology. 81(6). 555–558.
13.
Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526.
14.
Marín‐Aguilera, Mercedes, Natàlia Jiménez, Òscar Reig, et al.. (2020). Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells. 9(1). 203–203.
15.
Jiménez, Natàlia, Òscar Reig, Giancarlo Castellano, et al.. (2020). 1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients. Annals of Oncology. 31. S1107–S1107.
16.
Jiménez, Natàlia, Òscar Reig, Maria Milà‐Guasch, et al.. (2020). Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. Frontiers in Oncology. 10. 594023–594023.
17.
Reig, Òscar, Mercedes Marín‐Aguilera, Gemma Carrera, et al.. (2016). TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology. 70(5). 709–713.
18.
Mellado, Begoña, Natàlia Jiménez, Mercedes Marín‐Aguilera, & Òscar Reig. (2015). Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer. 14(4). 265–270.
19.
Marín‐Aguilera, Mercedes, Jordi Codony‐Servat, Òscar Reig, et al.. (2014). Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics. 13(5). 1270–1284.
20.
Liaño, Alfonso Gómez de, et al.. (2014). Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. British Journal of Cancer. 110(9). 2201–2208.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chia‐Chi Lin Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by Jamie McIntosh Breakdown of academic impact, for papers by Flavio Mavignier Cárcano Breakdown of academic impact, for papers by Tahsin M. Khan Breakdown of academic impact, for papers by Francesca Vignani Breakdown of academic impact, for papers by Émeline Colomba Breakdown of academic impact, for papers by Hielke J. Meulenbeld Breakdown of academic impact, for papers by Irene De Santo Breakdown of academic impact, for papers by Prabhakar Pandey